Author

Michelle A. Rudek

Professor of Oncology and Medicine, Johns Hopkins University - Cited by 11,328 - clinical pharmacology - cancer chemotherapy - drug development - AIDS Malignancy

Biography

Wprking as a professor in the division of Chemical Therapeutics, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Title
Cited by
Year
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial
SE Krown, CB Moser, P MacPhail, RM Matining, C Godfrey, SR Caruso, ...The Lancet 395 (10231), 1195-1207, 2020202
50
2020
A prospective study of peritransplant sorafenib for patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic transplantation
KW Pratz, MA Rudek, BD Smith, J Karp, I Gojo, A Dezern, RJ Jones, ...Biology of Blood and Marrow Transplantation 26 (2), 300-306, 2020202
28
2020
HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
S Salman, DJ Meyers, EE Wicks, SN Lee, E Datan, AM Thomas, ...The Journal of Clinical Investigation 132 (9), 2022202
27
2022
A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer
AG Murphy, M Zahurak, M Shah, CD Weekes, A Hansen, LL Siu, ...Clinical and translational science 13 (6), 1178-1188, 2020202
24
2020
Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: Results of a phase 1 clinical trial
GL Gallia, M Holdhoff, H Brem, AD Joshi, CL Hann, RY Bai, V Staedtke, ...Neuro-Oncology Advances 3 (1), vdaa154, 212
20
2021
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS …
SA Grossman, CG Romo, MA Rudek, J Supko, J Fisher, LB Nabors, ...Neuro-oncology 22 (10), 1422-1424, 2020202
19
2020
Phase I study of entinostat and nivolumab with or without ipilimumab in advanced solid tumors (ETCTN-9844)
ET Roussos Torres, C Rafie, C Wang, D Lim, A Brufsky, P LoRusso, ...Clinical Cancer Research 27 (21), 5828-5837, 2021202
17
2021
Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids
D Hernandez, L Palau, K Norsworthy, NM Anders, S Alonso, M Su, ...Leukemia 34 (11), 3077-3081, 2020202
13
2020
Targeting the Hedgehog pathway using itraconazole to prevent progression of Barrett’s esophagus to invasive esophageal adenocarcinoma
RJ Kelly, AM Ansari, T Miyashita, M Zahurak, F Lay, AK Ahmed, LJ Born, ...Annals of surgery 273 (6), e206, 2021202
12
2021
A phase Ib/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with 11q23-rearranged acute myeloid leukemia
A phase Ib/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with q23-rearranged acute myeloid leukemiaK Menghrajani, SF Cai, SM Devlin, SA Armstrong, R Piekarz, M Rudek, ...Blood 134, 2655, 2019201
11
2019
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax
BS Moses, S McCullough, JM Fox, BT Mott, SM Bentzen, MJ Kim, ...Blood Advances 5 (3), 711-724, 2021202
9
2021
Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies
LJ Savic, J Chapiro, E Funai, K Bousabarah, IT Schobert, E Isufi, ...European radiology 31, 3002-3014, 2021202
8
2021
Safety and efficacy of brentuximab vedotin in combination with avd in stage ii-iv hiv-associated classical hodgkin lymphoma: results of the phase 2 study, amc 085
Safety and efficacy of brentuximab vedotin in combination with avd in stage ii-iv hiv-associated classical hodgkin lymphoma: results of the phase 2 study, amc 05PG Rubinstein, PC Moore, M Bimali, A Chadburn, E Cesarman, M Rudek, ...Blood 134, 130, 2019201
8
2019
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review
SL Gerritse, JBE Janssen, M Labots, R de Vries, M Rudek, M Carducci, ...Cancer Treatment Reviews 97, 102171, 2021202
8
2021
Exosome-encased nucleic acid scaffold chemotherapeutic agents for superior anti-tumor and anti-angiogenesis activity
RP McNamara, AB Eason, Y Zhou, R Bigi, JD Griffith, LM Costantini, ...ACS bio & med chem Au 2 (2), 140-149, 2022202
5
2022
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
MW Saif, CR Becerra, MG Fakih, W Sun, L Popovic, S Krishnamurthi, ...Cancer Chemotherapy and Pharmacology 88 (3), 48-497, 2021202
5
2021
DPYD testing: Time to put patient safety first
SD Baker, SE Bates, GA Brooks, WL Dahut, RB Diasio, WS El-Deiry, ...Journal of clinical oncology: official journal of the American Society of …, 2023202
4
2023
Phase I and pharmacokinetic study of romidepsin in patients with cancer and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group Study
RM Connolly, E Laille, U Vaishampayan, V Chung, K Kelly, A Dowlati, ...Clinical Cancer Research 26 (20), 5329-5337, 2020202
4
2020
Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer
AA Date, M Kates, T Yoshida, T Babu, U Afzal, P Kanvinde, A Baras, ...Drug Delivery and Translational Research 11, 2085-2095, 2021202
3
2021
A novel 2-carbon-linked dimeric artemisinin with potent antileukemic activity and favorable pharmacology
AB Kagan, BS Moses, BT Mott, G Rai, NM Anders, MA Rudek, CI CivinFrontiers in Oncology 11, 79007, 2022202
3
2022

Referred From: https://scholar.google.com/citations?user=WLPxkBsAAAAJ&hl=en&oi=sra

Cited by
Citations 11328
h-index 59
i10-index 155
Recommended Journals
Open Access Journals